Clover Health Investments Corp’s recently made public that its CEO, Medicare Advantage Reynoso Jamie L. unloaded Company’s shares for reported $5332.0 on Oct 07 ’25. In the deal valued at $2.65 per share,2,012 shares were sold. As a result of this transaction, Reynoso Jamie L. now holds 3,043,172 shares worth roughly $8.49 million.
Then, JAMIE REYNOSO bought 2,012 shares, generating $5,271 in total proceeds.
Before that, Reynoso Jamie L. sold 4,914 shares. Clover Health Investments Corp shares valued at $15,184 were divested by the CEO, Medicare Advantage at a price of $3.09 per share. As a result of the transaction, Reynoso Jamie L. now holds 3,053,890 shares, worth roughly $8.52 million.
Craig Hallum initiated its Clover Health Investments Corp [CLOV] rating to a Buy in a research note published on December 17, 2024; the price target was $6. A number of analysts have revised their coverage, including UBS’s analysts, who began to cover the stock in early October with a ‘”a Neutral”‘ rating. Cowen also remained covering CLOV and has increased its forecast on February 02, 2022 with a “Market perform” recommendation from previously “an Underperform” rating. Canaccord Genuity started covering the stock on February 02, 2022. It rated CLOV as “a Buy”.
Price Performance Review of CLOV
On Tuesday, Clover Health Investments Corp [NASDAQ:CLOV] saw its stock jump 6.08% to $2.79. Over the last five days, the stock has gained 3.33%. Clover Health Investments Corp shares have fallen nearly -29.37% since the year began. Nevertheless, the stocks have fallen -11.43% over the past one year.
How much short interest is there in Clover Health Investments Corp?
A steep rise in short interest was recorded in Clover Health Investments Corp stocks on 2025-09-30, growing by 3.41 million shares to a total of 51.74 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 48.33 million shares. There was a rise of 6.59%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 19, 2022 when SVB Leerink began covering the stock and recommended ‘”a Mkt perform”‘ rating along with a $3 price target.
